This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Sanofi (SNY) Beats on Q3 Earnings, to Spin-Off Consumer Unit
by Zacks Equity Research
Sanofi (SNY) beats third-quarter estimates for earnings but misses the same for sales. It announces plans to separate its Consumer unit into a new public listed company.
Merck (MRK) Q3 Earnings Top Estimates, COVID Drug Boosts Sales
by Zacks Equity Research
Merck (MRK) beats Q3 estimates for earnings and sales. It raises its 2023 guidance. Stock rises in pre-market.
Eli Lilly (LLY) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
On Eli Lilly's (LLY) third-quarter conference call, investor focus is likely to be on the sales of its new diabetes drug, Mounjaro.
Astrazeneca (AZN) Stock Moves -0.56%: What You Should Know
by Zacks Equity Research
Astrazeneca (AZN) closed at $64.21 in the latest trading session, marking a -0.56% move from the prior day.
Moderna (MRNA) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Investors' focus will likely be on updates on Moderna's (MRNA) pipeline, especially its late-stage pipeline candidates, when it reports third-quarter earnings.
Amgen (AMGN) to Report Q3 Earnings: Will It Beat Estimates?
by Zacks Equity Research
Volume growth from Amgen's (AMGN) key drugs like Prolia, Repatha and Evenity, among others, is expected to have been partially offset by biosimilar/generic competition for mature drugs.
Pfizer (PFE) to Report Q3 Earnings: Here's What to Expect
by Zacks Equity Research
Pfizer (PFE) expects better non-COVID operational revenue growth sequentially in the third quarter, driven by its key products, new launches as well as newly acquired products.
What's in the Cards for Encompass Health (EHC) in Q3 Earnings?
by Zacks Equity Research
Encompass Health's (EHC) Q3 results are likely to reflect improved inpatient volumes and bed additions, offset by higher operating expenses.
GSK Gears Up for Q3 Earnings: Will It Surpass Estimates?
by Zacks Equity Research
We expect GSK's specialty products like Cabenuva, Juluca, Dovato, Bexsero, Trelegy Ellipta and Shingrix to drive third-quarter sales performance.
What's in the Cards for Universal Health (UHS) in Q3 Earnings?
by Zacks Equity Research
Universal Health's (UHS) Q3 results are likely to benefit from higher patient volumes at its acute care hospitals and behavioral health facilities, partly offset by increased physician expenses.
What's in Store for Bristol-Myers (BMY) in Q3 Earnings?
by Zacks Equity Research
Investors are likely to focus on Opdivo's demand along with an incremental contribution from newer drugs when Bristol-Myers (BMY) reports Q3 results.
Merck (MRK) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, when the company reports Q3 earnings.
AbbVie (ABBV) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
AbbVie's (ABBV) Q3 performance will likely reflect its newer immunotherapy drugs trying to compensate for declining Humira sales following the loss of U.S. exclusivity.
Novartis (NVS) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Investor focus is likely to be on the top and bottom-line numbers, and updates on guidance post-Sandoz spin-off when Novartis (NVS) reports its third-quarter results.
Why Astrazeneca (AZN) is a Top Value Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Astrazeneca (AZN) Falls More Steeply Than Broader Market: What Investors Need to Know
by Zacks Equity Research
The latest trading day saw Astrazeneca (AZN) settling at $64.42, representing a -1.26% change from its previous close.
Will Rising Costs Hurt HCA Healthcare's (HCA) Q3 Earnings?
by Zacks Equity Research
HCA Healthcare's (HCA) third-quarter results are likely to reflect an increased occupancy rate and a lower average length of stay.
Can Growing Visits Aid Teladoc's (TDOC) Earnings in Q3?
by Zacks Equity Research
Teladoc's (TDOC) third-quarter results are likely to reflect growth in BetterHelp paying users.
AstraZeneca PLC (AZN) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Zacks.com users have recently been watching Astrazeneca (AZN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Can Centene's (CNC) Q3 Earnings Beat on Membership Growth?
by Zacks Equity Research
Centene's (CNC) third-quarter results are likely to reflect higher premiums and lower cost of services.
AstraZeneca's (AZN) Tagrisso Combo Gets FDA's Priority Review
by Zacks Equity Research
The FDA accepts and grants priority review to AstraZeneca's (AZN) sNDA, seeking approval of Tagrisso combined with chemotherapy as a first-line treatment for EGFR-mutated advanced NSCLC. A decision is due in first-quarter 2024.
UnitedHealth Group (UNH) Q3 Earnings Beat, Boosts '23 EPS View
by Zacks Equity Research
UnitedHealth Group's (UNH) management presently forecasts adjusted net EPS between $24.85 and $25.00 for 2023.
J&J (JNJ) to Report Q3 Earnings, Its First After Unit Spin-Off
by Zacks Equity Research
J&J's (JNJ) third-quarter results are the first quarterly update for the new company after the Consumer Health spin-off.
Why the Market Dipped But (AZN) Gained Today
by Zacks Equity Research
Astrazeneca (AZN) concluded the recent trading session at $68.11, signifying a +0.15% move from its prior day's close.